MTVA MetaVia, Inc. Total Debt to Capital

Corporate emblem and logo of MetaVia Inc (MTVA)

MetaVia Inc (MTVA) develops unique neuroprotectors to protect brain cells during the early stages of degenerative pathologies. The business model relies on outsourcing preclinical research, where intellectual property control minimizes vendor lock-in risks. Market price action on GURU.Markets reflects a total debt-to-equity ratio of 0.03, complementing the company's strategy to implement precision medicine for the correction of severe metabolic failures.

MTVA: MetaVia, Inc. Total Debt to Capital 11/30/2024 - 10/28/2026

Comprehensive metric breakdowns and analytics for MetaVia (MTVA)

- price and consensus price forecast:
Price Chart MetaVia Inc.|MTVA - Broker Consensus Forecast
- market capitalization data:
Market Capitalization MetaVia|MTVA - Total Enterprise Value
- book capitalization data:
Accounting Value per Share MetaVia|MTVA - Book Capitalization|Market Value to Book Value Ratio metaviatx.com|MTVA - Aggregate Asset Value
- debt and liquidity data:
Debt to Equity MetaVia Inc|MTVA - Long-Term Liabilities to Capital|Short-Term Debt to Equity MetaVia Inc.|MTVA - Company Total Debt|Debts to Book Capitalization MetaVia|MTVA - Long-Term Debt|Company Current Liabilities MetaVia
Basic company analysis:MetaVia Inc MTVA
Product sample of MetaVia Inc.

Searching for fundamentally resilient assets requires analyzing the total liabilities-to-equity ratio, which allows for a real-time assessment of leverage and currency risks. For MetaVia Inc (MTVA), which enjoys high trust in the field of neurodegenerative research, this metric confirms the brand's financial stability, reflecting the debt-to-equity financial dependency trend on the GURU.Markets platform.

Analysis of competing companies

Debt to Equity Biogen (BIIB)|Debt to Equity Ratio Neurocrine|Regencell - Total Debt to Capital|Debt to Capital Axsome Corp AXSM|Total Debt to Equity Ratio ACAD (ACADIA Pharmaceuticals)|xenon-pharma.com - Total Debt to Capital|Debt to Equity Viking Therapeutics, Inc. (VKTX)|SUPN: All Debt to Shareholders' Equity Ratio|Debt to Equity CPRX|DNLI (Denali Corp) - Debt to Capital|Debt to Equity HRMY|Total Debt to Equity Ratio biohavenpharma.com|Amylyx Pharmaceuticals, Inc. - Total Debt to Capital|Debt to Capital Trevi Therapeutics Inc TRVI|Total Debt to Equity Ratio Praxis Medicines (PRAX)|Aggregate Debt to Capital Anavex Life Sciences Corp AVXL|CeriBell, Inc. - Total Debt to Capital|Prothena Corporation PLC (PRTA) - Total Debt to Capital|alector.com (ALEC) - Total Debt to Equity Ratio|Annexon Biosciences (ANNX) - Debt to Equity|OMER: Total Debt to Capital|Total Debt to Capital Coefficient Neurogene Therapeutics|Total Debt to Capital ACIU|Total Debt to Capital voyagertherapeutics.com VYGR|Total Debt to Equity Ratio Neumora Therapeutics, Inc.|All Debt to Shareholders' Equity Ratio Scilex Holding SCLX|Total Debt to Capital TVGN (Tevogen Bio Holdings, Inc.)|ACOG: Total Debt to Capital Coefficient|Debt to Equity Cognition Therapeutics|inhibikase.com (IKT) - Debt to Equity Ratio|Total Debt to Capital SAVA|Total Debt to Equity Ratio ASRT|Debt to Equity COYA (Coya Therapeutics, Inc.)|Total Debt to Equity Ratio vistagen.com VTGN|Total Debt to Equity Ratio Ovid Therapeutics (OVID)|ABOS - Aggregate Debt to Capital|CRVO - Total Debt to Equity Ratio|ATHE - Debt to Equity|CLNN: Total Debt to Capital|PEPG (PepGen) - Total Debt to Capital|Debt to Equity Jupiter Neurosciences Inc (JUNS)|Debt to Equity Ratio relmada.com|Annovis Bio - Total Debt to Capital|Debt to Capital gracetx.com GRCE|Total Debt to Equity Ratio AIFF (Firefly Neuroscience Inc)|ANEW Medical - Total Debt to Capital|Debt to Equity NeuroSense Therapeutics, Ltd. (NRSN)|RVPH: All Debt to Shareholders' Equity Ratio|Debt to Equity NRXS|HSDT (Helius Medical Technologies) - Debt to Capital|Debt to Equity PASG|Total Debt to Equity Ratio Neuphoria|Minerva Neurosciences - Total Debt to Capital|Debt to Capital athira.com ATHA|Total Debt to Equity Ratio Addex Therapeutics Ltd (ADXN)|Aggregate Debt to Capital Alzamend Neuro Inc. ALZN|Cyclerion - Total Debt to Capital|Protagenic Therapeutics (PTIX) - Total Debt to Capital|pasitheaclinics.com (KTTA) - Total Debt to Equity Ratio|Cortigent (CRGT) - Debt to Equity|ATXI: Total Debt to Capital|Total Debt to Capital Coefficient Brainstorm Cell Therapeutics Inc.|Total Debt to Capital CARA|Total Debt to Capital Chromocell CHRO|Total Debt to Equity Ratio Eliem Therapeutics Inc.|All Debt to Shareholders' Equity Ratio Intra-Cellular Therapies Inc. ITCI|Total Debt to Capital LBPH (Longboard Pharmaceuticals, Inc.)|MRNS: Total Debt to Capital Coefficient|Debt to Equity NKGen|NeuroBo Pharma (NRBO) - Debt to Equity Ratio|Total Debt to Capital SAGE|Total Debt to Equity Ratio SNPX|Debt to Equity TRVN (Trevena)|Total Debt to Equity Ratio vigilneuro.com VIGL|Total Debt to Equity Ratio Anew Medical (WENA)|CERE - Aggregate Debt to Capital